

EDITORIAL COMMENT

Taking the Last Hurdles: Magnetic Resonance Myocardial Perfusion Imaging*

Eike Nagel, MD, PhD

London, United Kingdom

In this issue of *iJACC*, Doesch et al. (1) assess the prognostic value of magnetic resonance (MR) adenosine stress perfusion in patients with coronary lesions of $\geq 50\%$ but $\leq 75\%$. This study closes an important gap in the decision-making process and may reduce the need for invasive hemodynamic studies in patients with intermediate stenoses.

The selection of patients with stable coronary artery disease (CAD) for invasive coronary angiography and revascularization and the prediction of the individual patient's risk of major cardiac events remain subjective and imprecise. Recent invasive studies, such as the DEFER (Deferral Versus Performance of PTCA in Patients Without Documented Ischemia) study have shown that revascularization does not improve the prognosis of

ularizing patients with stable angina pectoris as a whole (4). A subgroup analysis of the COURAGE data in patients with single-photon emission computed tomography (SPECT) suggests that the prognosis of patients is correlated to their ischemic burden after optimal medical therapy (with or without revascularization) and the amount of ischemia reduction achieved by therapy (5). That is in line with a wealth of data demonstrating that the prognosis of patients is related to the presence of stress-induced myocardial ischemia using SPECT (6–10), stress echocardiography (11–14), or cardiac MR (15,16). Specific data on patients with intermediate stenoses, however, are lacking.

Over the past 3 decades, SPECT and positron emission tomography (PET) have dominated myocardial perfusion imaging in clinical practice on the basis of an extensive amount of research. However, these techniques have several important limitations, such as the occurrence of attenuation artifacts for SPECT, the application of radioactive tracers, and the limited availability of PET, which is considered the reference standard. MR myocardial perfusion imaging has been shown to be highly accurate for the assessment of myocardial ischemia and was noninferior to SPECT in a recent multicenter trial (17). One of the major advantages of MR perfusion imaging is its ability to visualize subendocardial perfusion defects, which is not possible with PET or SPECT owing to their lower spatial resolution. More recently, MR perfusion imaging has been validated against invasive hemodynamic measurements, resulting in good correlations with coronary flow reserve and acceptable correlations with FFR (18–20).

To date, less clinical outcome information is available from MR myocardial perfusion imaging in comparison to nuclear medicine, which has been used for >30 years. However, these data are becoming available. A recent study (8) of adenosine

See page 424

patients with intermediate coronary artery stenosis, if the stenosis does not limit flow during stress (2). Usually, this is determined by measuring pressure proximal and distal to the stenosis using an intracoronary pressure wire (fractional flow reserve [FFR]). These single-center data have been reconfirmed in a multicenter setting in patients with multivessel disease, in the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study (3). Among others, the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial has challenged the benefit of revas-

*Editorials published in *JACC: Cardiovascular Imaging* reflect the views of the authors and do not necessarily represent the views of *JACC: Cardiovascular Imaging* or the American College of Cardiology.

From the Division of Imaging Sciences, King's College London, London, United Kingdom. Dr. Nagel has received grant support from Philips Healthcare, Bayer-Schering-Pharma Consultancy, GE Healthcare, Bayer-Schering-Pharma Speakers Bureau, Bayer-Schering-Pharma, and Daiichi-Sankyo.

stress perfusion cardiac MR in patients with chest pain, negative troponin-I test results, and nondiagnostic electrocardiographic findings demonstrated a sensitivity of 100% and a specificity of 93% for the detection of future adverse cardiac outcomes. Patients with normal stress myocardial perfusion had no adverse cardiac events during 1 year of follow-up. In another study by Jahnke et al. (16), a negative perfusion study was related with 0.7%, 0.7%, and 2.3% cumulative event rate for the first 3 years, which was significantly lower than the event rate in patients with a positive MR myocardial perfusion study (6.2%, 12.2%, and 16.3% cumulative event rate for the first 3 years).

Doesch et al. (1) have followed up a group of 81 patients with stable angina and intermediate coronary artery lesions by invasive angiography for 30 ± 8 months. All patients were treated with optimal medical therapy independent of the MR findings. In the group of 36 patients without a defect on adenosine stress MR perfusion, no major cardiac event was found during a follow-up period of 30 ± 8 months. In contrast, in the group of 45 patients with a perfusion defect, 9 (20%) had an acute coronary syndrome. Despite not being used for clinical decision making, the presence of a stress-induced perfusion defect was associated with a significantly higher rate of revascularization (37.8% vs. 5.5%). The presence or absence of a perfusion defect correlated with symptoms at an early

follow-up at 18 ± 8 months, but not at a late follow-up.

The study closes a growing gap. On one hand, revascularization should be restricted to patients with hemodynamically significant stenoses. Until now, the only evidence specifically for patients with intermediate stenoses was available for FFR, which either requires a second invasive procedure after the first diagnostic angiography, or a significant prolongation of the invasive study. On the other hand, the number of patients with a primary diagnosis based on multislice computed tomography is also increasing. For both groups, a noninvasive rapid test would be highly desirable. Based on the data from this study, we can now start using MR perfusion in this setting.

Future trials need to concentrate on several aspects. First, the data need to be reconfirmed in a larger group of patients, preferably in a multicenter setting. Second, it needs to be worked out whether an MR perfusion-guided strategy is superior to an MR blind strategy. Third, a direct comparison of an MR-guided strategy to an FFR-guided strategy needs to be performed.

Reprint requests and correspondence: Dr. Eike Nagel, King's College London BHF Centre of Excellence GSTT Biomedical Research Centre Division of Imaging Sciences, The Rayne Institute, 4th Floor Lambeth Wing, St. Thomas' Hospital, London SE1 7EH, United Kingdom. *E-mail:* eike.nagel@kcl.ac.uk.

REFERENCES

1. Doesch C, Seeger A, Doering J, et al. Risk stratification by adenosine stress cardiac magnetic resonance in patients with coronary artery stenoses of intermediate angiographic severity. *J Am Coll Cardiol* 2009;2:424-33.
2. Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally non-significant stenosis: 5-year follow-up of the DEFER study. *J Am Coll Cardiol* 2007;49:2105-11.
3. Tonino PA, De Bruyne B, Pijls NH, et al., FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med* 2009;360:213-24.
4. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356:1503-16.
5. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. *Circulation* 2008;117:1283-91.
6. Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. *J Am Coll Cardiol* 1995;26:639-47.
7. Elhendy A, Schinkel A, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. *J Nucl Cardiol* 2003;10:261-6.
8. Ingkanisorn WP, Kwong RY, Bohme NS, et al. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. *J Am Coll Cardiol* 2006;47:1427-32.
9. Pavin D, Delonca J, Siegenthaler M, Doat M, Rutishauser W, Righetti A. Long-term (10 years) prognostic value of a normal thallium-201 myocardial exercise scintigraphy in patients with coronary artery disease documented by angiography. *Eur Heart J* 1997;18:69-77.
10. Shaw LJ, Hachamovitch R, Heller GV, et al. Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. The Economics of Noninvasive Diagnosis (END) study group. *Am J Cardiol* 2000;86:1-7.
11. Marcovitz PA, Shayna V, Horn RA, Hepner A, Armstrong WF. Value of dobutamine stress echocardiography in determining the prognosis of patients with known or suspected coronary artery disease. *Am J Cardiol* 1996;78:404-8.
12. Wake R, Takeuchi M, Yoshitani H, et al. Role of contrast-enhanced dobutamine stress echocardiography in predicting outcome in patients with known or suspected coronary artery disease. *Echocardiography* 2006;23:642-9.

13. Marwick TH. Use of stress echocardiography for the prognostic assessment of patients with stable chronic coronary artery disease. *Eur Heart J* 1997;18 Suppl D:97-101.
14. Pingitore A, Picano E, Varga A, et al. Prognostic value of pharmacological stress echocardiography in patients with known or suspected coronary artery disease: a prospective, large-scale, multicenter, head-to-head comparison between dipyridamole and dobutamine test. Echo-Persantine International Cooperative (EPIC) and Echo-Dobutamine International Cooperative (EDIC) study groups. *J Am Coll Cardiol* 1999;34:1769-77.
15. Hundley WG, Morgan TM, Neagle CM, Hamilton CA, Rerkpattanapit P, Link KM. Magnetic resonance imaging determination of cardiac prognosis. *Circulation* 2002;106:2328-33.
16. Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. *Circulation* 2007;115:1769-76.
17. Schwitzer J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. *Eur Heart J* 2008;29:480-9.
18. Barmeyer AA, Stork A, Muellerleile K, et al. Contrast-enhanced cardiac MR imaging in the detection of reduced coronary flow velocity reserve. *Radiology* 2007;243:377-85.
19. Costa MA, Shoemaker S, Futamatsu H, et al. Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve. *J Am Coll Cardiol* 2007;50:514-22.
20. Kuhl HP, Katoh M, Buhr C, et al. Comparison of magnetic resonance perfusion imaging versus invasive fractional flow reserve for assessment of the hemodynamic significance of epicardial coronary artery stenosis. *Am J Cardiol* 2007;99:1090-5.

Key Words: cardiac magnetic resonance ■ myocardial perfusion ■ coronary artery disease ■ myocardial ischemia ■ prognosis.